Once again, Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) are running into roadblocks trying to win over payers with their new drug for severe eczema. The latest frustration is occurring in the U.K., where a government watchdog decided the drug would not be cost effective.
The cost estimates for the drug, which is known as Dupixent, were considered “too high” to be a “good use of National Health Services resources,” according to a draft guidelines that were released on Tuesday by the National Institute for Health and Care Excellence. The annual cost, based on list price, would be about $23,000 per year for 26 injections, according to a briefing report.
About the Author Reprints
